Prospective, Multicenter, Observational Study of Apatinib Single or Combined Capecitabine for Treatment of Patients With Metastatic Her-2 Negative Breast Cancer

Phase 2 Unknown 120 enrolled Hebei Medical University Fourth Hospital

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to assess the efficacy and safety of patients who receive apatinib single or combined capecitabine for treatment of patients with metastatic her-2 negative breast cancer.

Timeline

Start: 2016-11-24
Primary completion: 2018-11
Completion: 2019-05

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Capecitabine	Small molecule	1000 mg/m2	—
Subject	Rivoceranib	Small molecule	500 mg	Oral

Prospective, Multicenter, Observational Study of Apatinib Single or Combined Capecitabine for Treatment of Patients With Metastatic Her-2 Negative Breast Cancer

Summary

Timeline

Drugs

Indications